Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
4,584 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02737085 | the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL) | unknown | Phase 1 / Phase 2 | 40 | Southwest Hospital, ChinaOTHER | 1 | Sep 7, 2016 | clinicaltrials |
| NCT02862561 | Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Gastric Cancer | unknown | Phase 1 / Phase 2 | 40 | Shanghai International Medical CenterINDUSTRY | 1 | Sep 2, 2016 | clinicaltrials |
| NCT02862587 | Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer | unknown | Phase 1 / Phase 2 | 40 | Shanghai International Medical CenterINDUSTRY | 1 | Sep 2, 2016 | clinicaltrials |
| NCT02862613 | Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer | unknown | Phase 1 / Phase 2 | 40 | Shanghai International Medical CenterINDUSTRY | 1 | Sep 2, 2016 | clinicaltrials |
| NCT01935453 | A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer | completed | Phase 1 | 18 | OrienGene Biotechnology Ltd.INDUSTRY | 1 | Sep 1, 2016 | clinicaltrials |
| NCT02886897 | A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors | unknown | Phase 1 / Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Sep 1, 2016 | clinicaltrials |
| NCT00503711 | Phase I Chinese PK | completed | Phase 1 | 36 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Aug 31, 2016 | clinicaltrials |
| NCT01758367 | Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell Transplantation | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Aug 31, 2016 | clinicaltrials |
| NCT02523365 | HepaSphere Interventional Therapy Using Digital Subtraction Angiography(DSA) for Cervical Carcinoma | completed | Phase 1 / Phase 2 | 60 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Aug 29, 2016 | clinicaltrials |
| NCT02523404 | HepaSphere Interventional Therapy Using Digital Subtraction Angiography(DSA)for Lung Cancer | completed | Phase 1 / Phase 2 | 60 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Aug 29, 2016 | clinicaltrials |
| NCT02545556 | Liver Cancer HepaSphere Combined With Cryosurgery | completed | Phase 1 / Phase 2 | 60 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Aug 29, 2016 | clinicaltrials |
| NCT01682135 | A Study in Participants With Advanced Solid Tumors | completed | Phase 1 | 28 | Eli Lilly and CompanyINDUSTRY | 1 | Aug 26, 2016 | clinicaltrials |
| NCT02862028 | PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor (Lung, Liver and Stomach) | unknown | Phase 1 / Phase 2 | 20 | Shanghai International Medical CenterINDUSTRY | 1 | Aug 25, 2016 | clinicaltrials |
| NCT02876978 | Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma | unknown | Phase 1 | 20 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 1 | Aug 24, 2016 | clinicaltrials |
| NCT02844881 | Study of Apatinib and MASCT in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | The First People's Hospital of LianyungangOTHER | 1 | Aug 11, 2016 | clinicaltrials |
| NCT02859948 | A Study of SKLB1028 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia | unknown | Phase 1 | 18 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Aug 9, 2016 | clinicaltrials |
| NCT02456350 | Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies | unknown | Phase 1 | 36 | Shenzhen Second People's HospitalOTHER | 1 | Aug 3, 2016 | clinicaltrials |
| NCT02457650 | T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies | unknown | Phase 1 | 36 | Shenzhen Second People's HospitalOTHER | 1 | Aug 3, 2016 | clinicaltrials |
| NCT02398513 | Regorafenib Phase I Study in Mainland Chinese Patients | completed | Phase 1 | 18 | BayerINDUSTRY | 1 | Aug 1, 2016 | clinicaltrials |
| NCT02851589 | Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Aug 1, 2016 | clinicaltrials |
| NCT02844062 | Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme | unknown | Phase 1 | 20 | Beijing Sanbo Brain HospitalOTHER | 1 | Jul 26, 2016 | clinicaltrials |
| NCT02399735 | Safety Study of NK Cells From Sibship to Treat the Recurrence of HCC After Liver Transplantation | unknown | Phase 1 | 18 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Jul 21, 2016 | clinicaltrials |
| NCT02840617 | ICG-based Fluorescence Imaging in Localization of Prostate Cancer and Metastatic Lymph Nodes | unknown | Phase 1 | 50 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Jul 21, 2016 | clinicaltrials |
| NCT02418481 | Safety and Efficiency of γδ T Cell Against Breast Cancer(Her-, er-, and pr-) | completed | Phase 1 / Phase 2 | 40 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Jul 19, 2016 | clinicaltrials |
| NCT02425735 | Safety and Efficiency of γδ T Cell Against Hepatocellular Liver Cancer | completed | Phase 1 / Phase 2 | 40 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Jul 19, 2016 | clinicaltrials |
| NCT02523430 | HepaSphere Interventional Therapy Using Digital Subtraction Angiography(DSA) for Nasopharyngeal Carcinoma | completed | Phase 1 / Phase 2 | 60 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Jul 19, 2016 | clinicaltrials |
| NCT02822053 | Effectivity and Safety of Ultrasound-guided Percutaneously Laser Ablation for Refractory Neoplasms | unknown | Phase 1 / Phase 2 | 100 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jul 4, 2016 | clinicaltrials |
| NCT02822066 | Effectivity and Safety of Irreversible Electroporation for Refractory Neoplasms in Liver and Pancreas | unknown | Phase 1 / Phase 2 | 60 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jul 4, 2016 | clinicaltrials |
| NCT02816944 | Effectivity and Safety of Endoscopic Ultrasonography-guided Laser Ablation for Refractory Neoplasms | unknown | Phase 1 / Phase 2 | 80 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jun 30, 2016 | clinicaltrials |
| NCT02805829 | Combination Trastuzumab With Expanded Natural Killer Cells for Treating HER2-positive Gastric Cancer | unknown | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Jun 22, 2016 | clinicaltrials |
| NCT02809001 | The Effects of Autologous Fat Transfer on Preventing Expanded Skin From Expansion Failure | completed | Phase 1 / Phase 2 | 80 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jun 22, 2016 | clinicaltrials |
| NCT02122809 | Phase I Study of Chiauranib in Patients With Advanced Solid Tumors | completed | Phase 1 | 18 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Jun 17, 2016 | clinicaltrials |
| NCT02799680 | Allogeneic CART-33 for Relapsed/Refractory CD33+ AML | unknown | Phase 1 | 12 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Jun 15, 2016 | clinicaltrials |
| NCT01542294 | SOX as Adjuvant Chemotherapy for Resectable Gastric Cancer | unknown | Phase 1 / Phase 2 | 71 | Chinese Academy of Medical SciencesOTHER | 1 | Jun 14, 2016 | clinicaltrials |
| NCT02794961 | CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies | unknown | Phase 1 / Phase 2 | 10 | Kai Lin Xu; Jun Nian ZhengOTHER | 1 | Jun 9, 2016 | clinicaltrials |
| NCT02759536 | In-hospital Neutron Irradiator (IHNI)-Based Boron Neutron Capture Therapy (BNCT) in the Treatment of Malignant Melanoma | unknown | Phase 1 / Phase 2 | 30 | The Third Xiangya Hospital of Central South UniversityOTHER | 1 | Jun 7, 2016 | clinicaltrials |
| NCT02317471 | Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96 | unknown | Phase 1 / Phase 2 | 45 | Chinese PLA General HospitalOTHER | 1 | Jun 6, 2016 | clinicaltrials |
| NCT02651441 | D-CIK Combined With Chemotherapy for Non-Small Cell Lung Cancer(NSCLC) | unknown | Phase 1 / Phase 2 | 60 | Shenzhen Hornetcorn Bio-technology Company, LTDINDUSTRY | 1 | May 24, 2016 | clinicaltrials |
| NCT01680991 | A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease | completed | Phase 1 | 48 | Hoffmann-La RocheINDUSTRY | 1 | Apr 25, 2016 | clinicaltrials |
| NCT02749019 | Dual Integrin αvβ3 and GRPR Targeting PET Imaging in Breast Cancer Patients | unknown | Phase 1 | 40 | Peking Union Medical College HospitalOTHER | 1 | Apr 22, 2016 | clinicaltrials |
| NCT02453464 | A Phase Ib Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal Cancer | unknown | Phase 1 | 36 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 20, 2016 | clinicaltrials |
| NCT02737735 | The Effect on Decreasing Chemotherapeutic Toxicity and Increasing Anti-tumor Effect of Chinese Herbs Based on Syndrome Differentiation | unknown | Phase 1 | 200 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Apr 14, 2016 | clinicaltrials |
| NCT02671513 | A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients | unknown | Phase 1 | 30 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 12, 2016 | clinicaltrials |
| NCT02252913 | A Study of Safety and Pharmacokinetics of Volitinib With Docetaxel in Patients With Advanced Gastric Cancer | completed | Phase 1 | 25 | Hutchison Medipharma LimitedINDUSTRY | 1 | Apr 8, 2016 | clinicaltrials |
| NCT02727309 | A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients | unknown | Phase 1 / Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | Apr 4, 2016 | clinicaltrials |
| NCT00826384 | Transarterial Chemoembolization (TACE) Therapy of Hepatocellular Carcinoma (HCC) With Blocking Tumor Blood Temporarily and Enhancing Perfusion | completed | Phase 1 / Phase 2 | 352 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT02586285 | Effect of S-Adenosyl Methionine Treatment on Recurrence After Curative Resection of Hepatocellular Carcinoma | unknown | Phase 1 | 300 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT02587884 | Anti-recurrence Treatment of Postresection on HCC Patients With MVI Presence and Over-expression of ASPH | unknown | Phase 1 | 180 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT02724332 | Adjuvant Anti-Recurrence Treatment With Rapamycin on Early-stage HCC | completed | Phase 1 | 300 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT02717741 | A Study of Tafetinib in Chinese Patients With Advanced Solid Tumor | unknown | Phase 1 | 30 | Nanjing Yoko Biomedical Co., Ltd.INDUSTRY | 1 | Mar 24, 2016 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials